Development of β-cyclodextrin-based sustained release microparticles for oral insulin delivery

Drug Development and Industrial Pharmacy

Volumn 41, Issue 8, 2015, Pages 1288-1293

  D'Souza, Bernadette ^a   Bhowmik, Tuhin ^b   Uddin, Mohammad Nasir ^c   Oettinger, Carl ^d   D'Souza, Martin ^d  

^a SAMFORD UNIVERSITY   (United States)

^b Encompass Pharmaceutical Services Inc   (United States)

^c WINGATE UNIVERSITY   (United States)

^d MERCER UNIVERSITY   (United States)

Author keywords

Cyclodextrin; Insulin; Microparticles; Oral delivery; Spray drying; Sustained release

Indexed keywords

BETA CYCLODEXTRIN; INSULIN; NANOPARTICLE; POLYMER; ANTIDIABETIC AGENT; BETA CYCLODEXTRIN DERIVATIVE; DELAYED RELEASE FORMULATION; GLUCOSE BLOOD LEVEL; MICROSPHERE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; INCUBATION TIME; INSULIN RELEASE; INTESTINE FLUID; MACROPHAGE; MALE; NONHUMAN; RAT; SPRAY DRYING; STOMACH JUICE; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; CELL SURVIVAL; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, EXPERIMENTAL; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PHARMACOKINETICS; PHYSIOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ANIMALS; BETA-CYCLODEXTRINS; BLOOD GLUCOSE; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; HYPOGLYCEMIC AGENTS; MALE; MICROSPHERES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84938410075     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.947507     Document Type: Article

References (36)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-31.
2. Centers for Disease Control and Prevention. National Diabetes Statistics report 2014. Available from: www. cdc. gov/diabetes/pubs/ statsreport14.
3. Pillay TS, Makgoba MW. Molecular mechanisms of insulin resistance. S Afr Med J 1991;79:607-13.
4. Hamilton-Shield JP. Overview of neonatal diabetes. Endocr Dev 2007;12:12-23.
5. Korsgren O, Nilsson B. Improving islet transplantation: A road map for a widespread application for the cure of persons with type I diabetes. Curr Opin Organ Transplant 2009;14:683-7.
6. Heinemann L. New ways of insulin delivery. Int J Clin Pract Suppl 2010;166:29-40.
7. Klonoff DC. Technological advances in the treatment of diabetes mellitus: better bioengineering begets benefits in glucose measurement, the artificial pancreas, and insulin delivery. Pediatr Endocrinol Rev 2003;1:94-100.
8. Clement S, Dandona P, Still JG, Kosutic G. Oral modified insulin (HIM2) in patients with type 1 diabetes mellitus: results from a phase I/II clinical trial. Metabolism 2004;53:54-8.
9. Hinds KD, Campbell KM, Holland KM, et al. PEGylated insulin in PLGA microparticles: In vivo and in vitro analysis. J Control Release 2005;104:447-60.
10. Hoffman A, Qadri B. Eligen insulin-a system for the oral delivery of insulin for diabetes. IDrugs 2008;11:433-41.
11. Krishnankutty RK, Mathew A, Sedimbi SK, et al. Alternative routes of insulin delivery. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009; 34:933-48.
12. Henkin RI. Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: Mechanisms of action. Nutrition 2010;26: 33-9.
13. Ma EL, Ma H, Liu Z, et al. In vitro and in vivo evaluation of a novel oral insulin formulation. Acta Pharmacol Sin 2006;27:1382-8.
14. Geho WB, Geho HC, Lau JR, Gana TJ. Hepatic-directed vesicle insulin: A review of formulation development and preclinical evaluation. J Diabetes Sci Technol 2009;3:1451-9.
15. Klingler C, Muller BW, Steckel H. Insulin-micro-and nanoparticles for pulmonary delivery. Int J Pharm 2009;377:173-9.
16. Fix JA. Oral controlled release technology for peptides: status and future prospects. Pharm Res 1996;13:1760-4.
17. Lee HJ. Protein drug oral delivery: the recent progress. Arch Pharm Res 2002;25:572-84.
18. Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: barriers and developments. Bio Drugs 2005;19:165-77.
19. Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999;16:1735-42.
20. Jones AK, Bejugam NK, Nettey H, et al. Spray-dried doxorubicinalbumin microparticulate systems for treatment of multidrug resistant melanomas. J Drug Target 2010;19:427-33.
21. Uddin AN, Bejugam NK, Gayakwad SG, et al. Oral delivery of gastro-resistant microencapsulated typhoid vaccine. J Drug Target 2009;17:553-60.
22. Delie F, Blanco-Prieto MJ. Polymeric particulates to improve oral bioavailability of peptide drugs. Molecules 2005;10:65-80.
23. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000;21:2475-90.
24. Ye M, Kim S, Park K. Issues in long-term protein delivery using biodegradable microparticles. J Control Release 2010;146:241-60.
25. Daoud-Mahammed S, Grossiord JL, Bergua T, Amiel C. Selfassembling cyclodextrin based hydrogels for the sustained delivery of hydrophobic drugs. J Biomed Mater Res A 2008;86:736-48.
26. Hamishehkar H, Emami J, Najafabadi AR, et al. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin. Int J Pharm 2010;389:74-85.
27. Maltesen MJ, Bjerregaard S, Hovgaard L, et al. Quality by design-Spray drying of insulin intended for inhalation. Eur J Pharm Biopharm 2008;70:828-38.
28. Qian F, Mathias N, Moench P, et al. Pulmonary delivery of a GLP-1 receptor agonist, BMS-686117. Int J Pharm 2009;366: 218-20.
29. Jayanthan A, Incoronato A, Singh A, et al. Cytotoxicity drug combinability and biological correlates of ABT-737 against acute lymphoblastic leukemia cells with MLL rearrangement. Pediatr Blood Cancer 2011;56:353-60.
30. Schmidt C, Höcherl K, Bucher M. Regulation of renal glucose transporters during severe inflammation. Am J Physiology 2007;292:804-11.
31. Bhowmik T, D'Souza B, Uddin MN, D'Souza MJ. Oral delivery of microparticles containing plasmid DNA encoding hepatitis B surface antigen. J Drug Target 2012;20:364-71.
32. Sarmento B, Ribeiro A, Veiga F, et al. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 2007;8:3054-60.
33. Eldridge JH, Meulbroek JA, Staas JK, et al. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol 1989; 251:191-202.
34. Sajeesh S, Bouchem K, Marsaud V, et al. Cyclodextrin complexed insulin encapsulated hydrogel microparticles: An oral delivery system for insulin. J Control Release 2010;147:377-84.
35. Pessin JE, Saltiel AR. Signaling pathways in insulin action: Molecular targets of insulin resistance. J Clin Invest 2000;106: 165-9.
36. Petersen K, Shulman GI. Cellular mechanism of insulin resistance in skeletal muscle. J R Soc Med 2002;95:8-13.